Clinical Trial Update: Low-dose Gemcitabine Combined With Nivolumab for Second-line and Above Line Treatment of NSCLC [Phase 4]

View source ↗

Summary

Phase 4 trial investigating low-dose gemcitabine in combination with nivolumab for second-line and later treatment in metastatic non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• nivolumab (nivolumab)

Snippet

Sponsor: Henan Cancer Hospital | Conditions: Non-small Cell Lung Cancer Metastatic | Phase 4 | Status: UNKNOWN